TINAVI(SH:688277)2021-10-27 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥28,400,541.21, representing a decrease of 1.00% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥25,057,757.08, with a year-to-date loss of ¥63,764,563.64[5]. - Total revenue for the first three quarters of 2021 reached ¥104,797,152.65, a significant increase from ¥76,443,945.53 in the same period of 2020, representing an increase of approximately 37.2%[22]. - The company reported a net loss of ¥73,953,293.91 for the first three quarters of 2021, compared to a net loss of ¥59,685,979.29 in the same period of 2020, indicating a worsening of approximately 24.0%[23]. - The net loss for Q3 2021 was approximately ¥64.20 million, compared to a net loss of ¥53.47 million in Q3 2020, representing an increase in loss of about 20% year-over-year[24]. - The total comprehensive loss attributable to the parent company was approximately ¥62.55 million in Q3 2021, compared to a loss of ¥55.94 million in the same period last year, indicating a 12% increase in loss[25]. - The basic and diluted earnings per share for Q3 2021 were both -¥0.15, compared to -¥0.13 in Q3 2020[25]. Research and Development - Research and development (R&D) expenses totaled ¥23,187,664.24 for the quarter, an increase of 100.44% year-on-year, and accounted for 81.65% of operating revenue, up 41.32 percentage points[6][11]. - The increase in R&D investment was attributed to higher material and design development costs, as well as an increase in R&D personnel and their average salaries[11]. - Research and development expenses surged to ¥69,879,548.32 in the first three quarters of 2021, up from ¥42,633,472.36 in 2020, reflecting a growth of approximately 63.9%[23]. - The company plans to raise up to 1.34 billion RMB to establish a comprehensive R&D, sales, and operation system to support its orthopedic surgical robot platform[15]. - The company emphasizes the importance of investor awareness regarding the risks associated with its ongoing research and development projects[15]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,144,637,865.76, reflecting a 2.27% increase from the end of the previous year[6]. - As of September 30, 2021, total assets amounted to ¥1,144,637,865.76, a slight increase from ¥1,119,280,166.10 at the end of 2020[20]. - Current assets decreased to ¥549,305,426.55 from ¥794,320,929.73 at the end of 2020, representing a decline of approximately 30.9%[20]. - Total liabilities increased to ¥168,282,729.57 from ¥92,729,036.15 at the end of 2020, reflecting an increase of approximately 81.4%[20]. - The company's equity attributable to shareholders decreased to ¥945,467,212.20 from ¥996,031,484.25 at the end of 2020, a decline of about 5.1%[20]. - The company has reported a significant increase in accounts receivable, which rose to ¥33,873,216.34 from ¥15,915,481.94, marking an increase of approximately 112.5%[20]. Cash Flow - The company reported a cash flow from operating activities of -¥82,650,277.44 year-to-date[6]. - Cash inflows from operating activities for the first three quarters of 2021 totaled approximately ¥153.51 million, an increase from ¥111.31 million in the same period of 2020[26]. - The net cash outflow from operating activities for Q3 2021 was approximately ¥82.65 million, an improvement from a net outflow of ¥113.02 million in Q3 2020[27]. - The total cash and cash equivalents at the end of Q3 2021 were approximately ¥416.63 million, a decrease from ¥437.28 million at the end of Q3 2020[27]. - The company received cash from sales of goods and services amounting to approximately ¥82.55 million in the first three quarters of 2021, slightly down from ¥83.84 million in the same period of 2020[26]. Market and Product Development - The company has developed a surgical robot integrated with an ultrasonic bone knife system, which has successfully assisted in three surgeries, marking a significant advancement in orthopedic surgery technology[15]. - The "Tianji 2.0" orthopedic surgical robot was approved for market launch in February 2021, indicating a growth trend in the company's product lineup[15]. - The Beijing Medical Insurance Bureau has included the company's robotic-assisted orthopedic surgeries and disposable robotic instruments in the medical insurance payment directory, effective October 23, 2021[16]. - The inclusion in the medical insurance payment category is expected to positively impact the promotion of the company's products and increase the volume of orthopedic robotic surgeries[16]. - The company is focusing on expanding its market presence and enhancing its competitive edge in the orthopedic surgery sector[15]. Shareholder Information - The top shareholder, Zhang Songgen, holds 18.02% of the shares, while the second-largest shareholder, Beijing Zhihui Hechuang Investment Partnership, holds 7.87%[14]. - The company has a total of 15,668 common shareholders at the end of the reporting period[14].